Gilead Sciences Inc
(GILD-NASDAQ)
DRUGS - Biotechnology
Stock report updated on 01/20/2012
- GILD is at or near its 52-week high. Studies have found that such stocks have an increased probability of outperforming the market over the next year.
- With a 24.3% return in the past year, this stock outperformed 90 percent of stocks in the S&P-100.
- GILD is one of this month's top performers with a return of 24.3%, beating 90 percent of stocks in the S&P-100.
- Up 5.7%, GILD is one of this week's biggest gainers.
- Volatility is forecast to fall over the next month.
- With RSI > 70, GILD is overbought. Odds slightly favor a short-term price reversal.
- Price broke above prior resistance level - a short-term bullish signal.
| Closing price: |
$47.44 |
| Support price level: |
$40.76 |
| Resistance price level: |
N/A |
| Relative strength index (14-day RSI): |
95.3 |
| Beta: |
0.95 |
52-Week Range
| Low |
High |
Price as % of Range |
| $35.34 |
$47.51 |
99.5% |
Moving Averages
| 200 day |
50 day |
20 day |
10 day |
| $40.39 |
$40.73 |
$42.84 |
$45.24 |
Volatility (annualized std. dev.)
Historical
(5 year) |
Last month |
Current estimate |
Next month forecast |
| 32.3% |
36.4% |
21.0% |
24.6% |
Value at Risk
There is an estimated 5% probability that the stock price of Gilead Sciences Inc will fall by more than:
- 5.7% in the next week.
- 13.9% in the next month.
- 56.9% in the next year.
Company News for Gilead Sciences Inc
Google Finance |
MSN Money |
Reuters
Reports for Other Stocks
